Table 3 Distribution of Clinical-pathological covariates according to the presence of PI3KCA mutations in 264 gastric cancers.
Parameter | Categories | Wt | Mutated | Odds Ratio (95% CI) | P |
|---|---|---|---|---|---|
Gender | F | 74 (83.1%) | 15 (16.9%) | 1 | 0.766 |
| Â | M | 148 (84.6%) | 27 (15.4%) | 0.9 (0.5 - 1.8) | Â |
Age | mean | 67.47 | 66.81 | Â | 0.771 |
pT | 2 | 88 (88.9%) | 11 (11.1%) | 1 | 0.077 |
| Â | 3 | 108 (83.7%) | 21 (16.3%) | 1.6 (0.7 - 3.5) | Â |
| Â | 4 | 26 (72.2%) | 10 (27.8%) | 3.1 (1.2 - 8.1) | Â |
pN | 0 | 42 (80.8%) | 10 (19.2%) | 1 | 0.840 |
| Â | 1 | 86 (86.0%) | 14 (14.0%) | 0.7 (0.3 - 1.7) | Â |
| Â | 2 | 67 (83.8%) | 13 (16.2%) | 0.8 (0.3 - 2.1) | Â |
| Â | 3 | 26 (86.7%) | 4 (13.3%) | 0.6 (0.2 - 2.2) | Â |
pM | 0 | 182 (85.0%) | 32 (15.0%) | 1 | 0.298 |
| Â | 1 | 24 (77.4%) | 7 (22.6%) | 1.7 (0.6 - 4.0) | Â |
Lauren | Intestinal | 147 (86.5%) | 23 (13.5%) | 1 | 0.275 |
| Â | Mixed | 22 (81.5%) | 5 (18.5%) | 1.5 (0.5 - 4.0) | Â |
| Â | Diffuse | 49 (77.8%) | 14 (22.2%) | 1.8 (0.9 - 3.8) | Â |
Location | Antrum | 93 (86.9%) | 14 (13.1%) | 1 | 0.394 |
| Â | Body | 58 (79.5%) | 15 (20.5%) | 1.7 (0.8 - 3.9) | Â |
| Â | Fundus | 59 (85.5%) | 10 (14.5%) | 1.1 (0.5 - 2.7) | Â |
Grading | G1 | 13 (86.7%) | 2 (13.3%) | 1 | 0.652 |
| Â | G2 | 76 (87.4%) | 11 (12.6%) | 0.9 (0.2 - 6.5) | Â |
| Â | G3 | 117 (83.0%) | 24 (17.0%) | 1.3 (0.3 - 8.9) | Â |
Microsatellite instability | MSI | 31 (79.5%) | 8 (20.5%) | 1 | 0.408 |
| Â | MSS | 191 (84.9%) | 34 (15.1%) | 0.7 (0.3 - 1.7) | Â |
Survival rate at 2 years (95% CI) | Â | 46.7% (40.5%-53.9%) | 46.9% (32.4%-67.8%) | Â | 0.941 |